The Worldwide Asthma Drugs Industry is Expected to Reach $34 Billion by 2028 – ResearchAndMarkets.com

The Worldwide Asthma Drugs Industry is Expected to Reach $34 Billion by 2028 – ResearchAndMarkets.com




The Worldwide Asthma Drugs Industry is Expected to Reach $34 Billion by 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Asthma Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Medications, Route of Administration, and Distribution Channels” report has been added to ResearchAndMarkets.com’s offering.

The asthma drugs market is projected to reach US$ 34,136.10 million in 2028 from US$ 24,239.17 million in 2021; it is estimated to grow at a CAGR of 5.0 % during 2021-2028.

The report highlights trends prevailing in the market and factors driving the market growth. The asthma drug market growth is attributed to the growing environmental implications & genetic implications of air pollution, more vulnerability in specific ethnic groups, growing exposure to coarse particulate matters, and growing prevalence of physiological disorders harboring asthma. However, unmet medical needs and lack of treatment adherence hamper the asthma drug market growth.

Asthma is a chronic respiratory condition marked by fluctuating airflow restriction, bronchial hyperresponsiveness, and airways inflammation. According to a review paper titled “Impact of Air Pollution on Asthma Outcomes” by Tiotiu et.al., air pollution hampered asthma outcomes in adults and children. Air pollution from traffic, nitrogen dioxide (NO2), and second hand smoking (SHS) are all substantial risk factors for the development of asthma in children. Asthma symptoms, exacerbations, and decreased lung function can be triggered by exposure to outside pollution.

In the US, exposure to air pollution continues to be associated with asthma. This severe and life-threatening chronic respiratory condition impacts the quality of life of more than ~23 million American citizens. Air pollution can aggravate asthma symptoms, triggering asthma attacks among people. Children with asthma, which affects ~6 million children in the US, are particularly vulnerable to pollution.

A new study financed by the Environmental Protection Agency (EPA) analyzed the link between air pollution and asthma. While experts cannot determine the primary asthma-causing agent due to air pollution, evidence suggests that it suppresses genes that control the immune system to distinguish between an allergen and a hazardous foreign substance, such as a virus or bacteria. The immune system then goes into overdrive, triggering an inflammatory reaction regardless of whether the drug is toxic, resulting in asthma.

Researchers from Stanford University’s Children’s Center investigated the effect of air pollution on two genes involved in immunological tolerance in children from an area with high levels of pollution. They discovered that short- and long-term exposure to high amounts of carbon monoxide (CO), NO2, and particulate matter) (PM2.5) were linked to changes in these two genes, which caused asthma. These findings focused on the epigenetic impacts of air pollution exposure and could help develop preventative asthma medicines.

Each of these asthma research improved the understanding of asthma in children and supplied crucial information to the EPA that can be used to protect human health and the environment. Through these research works, the drug discovery and development for asthma is being expedited, which is driving the asthma drug market.

The COVID-19 crisis created a public health and economic crisis in many countries worldwide. The pandemic adversely affected a large percentage of the population in the first half of 2020. With the virus affecting the respiratory system primarily, individuals with respiratory disorders were at a considerably higher risk of mortality and complications. For this, various organizations such as the Centers for Disease Control & Prevention, Asthma & Allergy Foundation of America, the World Health Organization, and the European Respiratory Society published guidelines, standards, and norms for patient care, differentiation of COVID-19 from other flu-like diseases, asthma, and allergies, and steps to avoid contracting COVID-19 in an asthmatic patient.

Various recommendations were also released, such as stocking up on asthma drugs to prevent the shortage of drugs for asthmatic patients. Various organizations, such as the WHO, concluded that the risk of infection was higher in people with asthma, leading to further exacerbation of asthma. The WHO also mentions that people with asthma who appear more vulnerable to worse outcomes included those who also had chronic obstructive pulmonary disease and people with non-allergic asthma compared to allergic asthma. Older age and non-white ethnicity also appear to confer greater risk, as expected from data from the general population.

Market Dynamics

Drivers

  • Growing Environmental Implications & Genetic Implications of Air Pollution
  • More Vulnerability in Specific Ethnic Groups
  • Growing Exposure to Coarse Particulate Matters
  • Growing Prevalence of Physiological Disorders Harboring Asthma

Restraints

  • Unmet Medical Needs
  • Lack of Treatment Adherence

Opportunities

  • Opportunities with Commercialization of Biologics
  • Future Trends
  • Increasing Research Activities and Product Innovations

Companies Mentioned

  • AstraZeneca
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • Merck & Co. Inc.
  • Koninklijke Philips NV
  • Sanofi
  • Pfizer Inc.
  • Novartis AG
  • Abbott

For more information about this report visit https://www.researchandmarkets.com/r/qbwg6m

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900